Boston Scientific Corporation
BSX
$102.86
-$0.43-0.42%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.66% | 16.45% | 46.09% | 100.55% | 96.67% |
| Total Depreciation and Amortization | 6.17% | 6.10% | 4.84% | 5.77% | 5.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 85.15% | 59.71% | 129.66% | 35.96% | -16.29% |
| Change in Net Operating Assets | 59.90% | 40.00% | -122.43% | -133.73% | -17.02% |
| Cash from Operations | 53.90% | 37.24% | 24.78% | 23.86% | 39.63% |
| Capital Expenditure | -2.44% | -11.11% | -18.90% | -28.41% | -34.78% |
| Sale of Property, Plant, and Equipment | 100.00% | -50.00% | -100.00% | -83.33% | -85.71% |
| Cash Acquisitions | -225.83% | -156.21% | -97.94% | 18.46% | -232.51% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -140.35% | -362.50% | -487.80% | -236.84% | -225.27% |
| Cash from Investing | -148.51% | -120.94% | -78.17% | -4.27% | -157.87% |
| Total Debt Issued | -17.53% | -- | -- | 1,901.71% | 1,057.59% |
| Total Debt Repaid | -145.97% | -13,125.00% | -13,125.00% | -53,200.00% | -53,200.00% |
| Issuance of Common Stock | 33.17% | 26.37% | 19.02% | 17.86% | 35.37% |
| Repurchase of Common Stock | -55.36% | -55.36% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 100.00% | 100.00% | 74.55% |
| Other Financing Activities | -61.22% | -75.28% | -25.68% | 57.53% | 79.50% |
| Cash from Financing | -70.91% | 36,180.00% | 18,044.44% | 825.00% | 368.90% |
| Foreign Exchange rate Adjustments | 418.18% | -175.00% | 140.00% | -50.00% | -22.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 200.00% | -100.00% |
| Net Change in Cash | -191.00% | -542.86% | 138.52% | 1,407.41% | 641.03% |